BACKGROUND: Ewing's tumors (ET) are rare in patients over the age of 40 years. Published data on presentation, treatment, and clinical outcome are limited. PATIENTS AND METHODS: We present a retrospective analysis of data from 47 patients in this age group diagnosed with ET and enrolled in the 2 consecutive trials, EICESS 92 and EURO-E.W.I.N.G. 99. The median age at diagnosis was 47.7 years (range, 40-68.6 years). RESULTS: The median follow-up was 2.23 years from diagnosis (range, 0.35-12.92 years). 72.3% of patients were found to have localized disease, and 27.7% had primary metastases. Good clinical response to induction therapy was observed in 55%, and 73% of patients showed good histological response. The event-free survival was 0.77 at 1 year and 0.50 at 3 years (n = 44). CONCLUSION: ET are rare in patients over the age of 40 years. With adequate multimodal therapy, the results in terms of survival are comparable to those in adolescence. Specific age-adapted treatment regimens are not established. Patients should be enrolled in international trials, and if necessary treatment should be adjusted for lower tolerance and co-morbidity. Copyright 2008 S. Karger AG, Basel.
BACKGROUND:Ewing's tumors (ET) are rare in patients over the age of 40 years. Published data on presentation, treatment, and clinical outcome are limited. PATIENTS AND METHODS: We present a retrospective analysis of data from 47 patients in this age group diagnosed with ET and enrolled in the 2 consecutive trials, EICESS 92 and EURO-E.W.I.N.G. 99. The median age at diagnosis was 47.7 years (range, 40-68.6 years). RESULTS: The median follow-up was 2.23 years from diagnosis (range, 0.35-12.92 years). 72.3% of patients were found to have localized disease, and 27.7% had primary metastases. Good clinical response to induction therapy was observed in 55%, and 73% of patients showed good histological response. The event-free survival was 0.77 at 1 year and 0.50 at 3 years (n = 44). CONCLUSION: ET are rare in patients over the age of 40 years. With adequate multimodal therapy, the results in terms of survival are comparable to those in adolescence. Specific age-adapted treatment regimens are not established. Patients should be enrolled in international trials, and if necessary treatment should be adjusted for lower tolerance and co-morbidity. Copyright 2008 S. Karger AG, Basel.
Authors: A Raciborska; K Bilska; K Drabko; E Michalak; R Chaber; M Pogorzała; K Połczyńska; G Sobol; M Wieczorek; K Muszyńska-Rosłan; M Rychlowska-Pruszyńska; C Rodriguez-Galindo; M Dziuk Journal: Clin Transl Oncol Date: 2015-08-07 Impact factor: 3.405
Authors: Christoph Minichsdorfer; Oskar Steinbrecher; Marita KÖlz; Maximilian Schmid; Markus Raderer; Thomas Brodowicz; Wolfgang Lamm Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Dagmar Adamkova Krakorova; Katerina Kubackova; Ladislav Dusek; Tomas Tomas; Pavel Janicek; Stepan Tucek; Jana Prausova; Igor Kiss; Iva Zambo Journal: Pathol Oncol Res Date: 2017-08-12 Impact factor: 3.201
Authors: Erin E Karski; Elizabeth McIlvaine; Mark R Segal; Mark Krailo; Holcombe E Grier; Linda Granowetter; Richard B Womer; Paul A Meyers; Judy Felgenhauer; Neyssa Marina; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2015-08-10 Impact factor: 3.167
Authors: Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig Journal: Curr Treat Options Oncol Date: 2009-06-17
Authors: Erin E Karski; Katherine K Matthay; John M Neuhaus; Robert E Goldsby; Steven G Dubois Journal: Cancer Epidemiol Date: 2012-09-05 Impact factor: 2.984